Top

Clinical Sarcoma Research

Published in:

Open Access 01-12-2015 | Research

Primary and secondary angiosarcomas: a comparative single-center analysis

Authors: Thorsten Hillenbrand, Franka Menge, Peter Hohenberger, Bernd Kasper

Published in: Clinical Sarcoma Research | Issue 1/2015

Abstract

Background

Angiosarcomas (AS) are rare vascular malignancies. They are subdivided into primary (PAS) and secondary angiosarcomas (SAS). The objective was to compare the characteristics of AS subtypes.

Methods

Eighteen PAS and ten SAS patients treated at our institution between 2004 and 2012 were included in this study.

Results

Median age of PAS and SAS patients was 52.9 and 64.2 years, respectively (p = 0.1448). The percentage of women was 27.8% for PAS, but 80.0% for SAS (p = 0.0163). While PAS occurred throughout the body, the majority of SAS arose from the breast (p = 0.0012). All SAS were radiation-induced with a median latency of 7.7 years. The majority of patients with PAS and SAS underwent surgery as primary or recurrence treatment (p > 0.95). Local recurrence was developed by 27.8% of PAS and 50.0% of SAS (p = 0.4119). 61.1% of PAS metastasized, but only 40.0% of SAS (p = 0.4328). Median overall survival for PAS and SAS was 19 and 57 months, respectively (p = 0.2306).

Conclusion

Radical surgery remains the mainstay of both primary and recurrence treatment. SAS show a high local recurrence rate, while PAS tend towards developing early metastases. Overall, prognosis is poor for both groups.

Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere D et al (2001) Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 91:1914–1926CrossRefPubMed

Weiss SW, Goldblum JR (2001) Malignant vascular tumors. In: Weiss SW, Goldblum JR (eds) Enzinger and Weiss’s soft tissue tumors, 4th edn. Mosby, St. Louis, pp 917–954

Nascimento AF, Raut CP, Fletcher CD (2008) Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. Am J Surg Pathol 32:1896–1904CrossRefPubMed

Torres KE, Ravi V, Kin K, Yi M, Guadagnolo BA, May CD et al (2013) Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol 20:1267–1274CrossRefPubMed

Fraga-Guedes C, Gobbi H, Mastropasqua MG, Botteri E, Luini A, Viale G (2012) Primary and secondary angiosarcomas of the breast: a single institution experience. Breast Cancer Res Treat 132:1081–1088CrossRefPubMed

Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ (2010) Angiosarcoma. Lancet Oncol 11:983–991CrossRefPubMed

Hung J, Hiniker SM, Lucas DR, Griffith KA, McHugh JB, Meirovitz A et al (2013) Sporadic versus radiation-associated angiosarcoma: a comparative clinicopathologic and molecular analysis of 48 cases. Sarcoma. doi:10.1155/2013/798403

Guo T, Zhang L, Chang NE, Singer S, Maki RG, Antonescu CR (2011) Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosom Cancer 50:25–33CrossRefPubMedCentralPubMed

Manner J, Radlwimmer B, Hohenberger P, Mossinger K, Kuffer S, Sauer C et al (2010) MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol 176:34–39CrossRefPubMedCentralPubMed

10.

Abraham JA, Hornicek FJ, Kaufman AM, Harmon DC, Springfield DS, Raskin KA et al (2007) Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol 14:1953–1967CrossRefPubMed

11.

Fayette J, Martin E, Piperno-Neumann S, Le Cesne A, Robert C, Bonvalot S et al (2007) Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol 18:2030–2036CrossRefPubMed

12.

Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG (2005) A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 11:241–247CrossRefPubMed

13.

Mark RJ, Poen JC, Tran LM, Fu YS, Juillard GF (1996) Angiosarcoma. A report of 67 patients and a review of the literature. Cancer 77:2400–2406CrossRefPubMed

14.

Pawlik TM, Paulino AF, McGinn CJ, Baker LH, Cohen DS, Morris JS et al (2003) Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer 98:1716–1726CrossRefPubMed

15.

Fata F, O’Reilly E, Ilson D, Pfister D, Leffel D, Kelsen DP et al (1999) Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86:2034–2037CrossRefPubMed

16.

Italiano A, Cioffi A, Penel N, Levra MG, Delcambre C, Kalbacher E et al (2012) Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer 118:3330–3336CrossRefPubMed

17.

Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S et al (2008) Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 26:5269–5274CrossRefPubMed

18.

Maki RG, D’Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD et al (2009) Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27:3133–3140CrossRefPubMedCentralPubMed

19.

Buehler D, Rice SR, Moody JS, Rush P, Hafez GR, Attia S et al (2014) Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience. Am J Clin Oncol 37:473–479CrossRefPubMed

20.

Lahat G, Dhuka AR, Hallevi H, Xiao L, Zou C, Smith KD et al (2010) Angiosarcoma: clinical and molecular insights. Ann Surg 251:1098–1106CrossRefPubMed

21.

Strobbe LJ, Peterse HL, van Tinteren H, Wijnmaalen A A, Rutgers EJ (1998) Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforseen sequela. Breast Cancer Res Treat 47:101–109CrossRefPubMed

22.

De Smet S, Vandermeeren L, Christiaens MR, Samson I, Stas M, Van Limbergen E et al (2008) Radiation-induced sarcoma: analysis of 46 cases. Acta Chir Belg 108:574–579PubMed

23.

Blanchard DK, Reynolds C, Grant CS, Farley DR, Donohue JH (2002) Radiation-induced breast sarcoma. Am J Surg 184:356–358CrossRefPubMed

24.

Seinen JM, Styring E, Verstappen V, Vult von Steyern F, Rydholm A, Suurmeijer AJ et al (2012) Radiation-associated angiosarcoma after breast cancer: high recurrence rate and poor survival despite surgical treatment with R0 resection. Ann Surg Oncol 19:2700–2706CrossRefPubMedCentralPubMed

25.

Ge Y, Ro JY, Kim D, Kim CH, Reardon MJ, Blackmon S et al (2011) Clinicopathologic and immunohistochemical characteristics of adult primary cardiac angiosarcomas: analysis of 10 cases. Ann Diagn Pathol 15:262–267CrossRefPubMed

26.

Morgan MB, Swann M, Somach S, Eng W, Smoller B (2004) Cutaneous angiosarcoma: a case series with prognostic correlation. J Am Acad Dermatol 50:867–874CrossRefPubMed

27.

Jallali N, James S, Searle A, Ghattaura A, Hayes A, Harris P (2012) Surgical management of radiation-induced angiosarcoma after breast conservation therapy. Am J Surg 203:156–161CrossRefPubMed

28.

Riad S, Biau D, Holt GE, Werier J, Turcotte RE, Ferguson PC et al (2012) The clinical and functional outcome for patients with radiation-induced soft tissue sarcoma. Cancer 118:2682–2692CrossRefPubMed

29.

Skubitz KM, Haddad PA (2005) Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 104:361–366CrossRefPubMed

30.

Ray-Coquard I, Italiano A, Bompas E, Le Cesne A, Robin YM, Chevreau C et al (2012) Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO). Oncologist 17:260–266CrossRefPubMedCentralPubMed

31.

Lindet C, Neuville A, Penel N, Lae M, Michels JJ, Trassard M et al (2013) Localised angiosarcomas: the identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO). Eur J Cancer 49:369–376CrossRefPubMed

32.

Vorburger SA, Xing Y, Hunt KK, Lakin GE, Benjamin RS, Feig BW et al (2005) Angiosarcoma of the breast. Cancer 104:2682–2688CrossRefPubMed

33.

Blay JY, van Glabbeke M, Verweij J, van Oosterom AT, Le Cesne A, Oosterhuis JW et al (2003) Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 39:64–69CrossRefPubMed

Title: Primary and secondary angiosarcomas: a comparative single-center analysis
Authors: Thorsten Hillenbrand
Franka Menge
Peter Hohenberger
Bernd Kasper
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Clinical Sarcoma Research / Issue 1/2015
Electronic ISSN: 2045-3329
DOI: https://doi.org/10.1186/s13569-015-0028-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2015

Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma

A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma

Older soft tissue sarcoma patients experience increased rates of venous thromboembolic events: a retrospective cohort study of SEER-Medicare data

Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma

Retroperitoneal solitary fibrous tumor: surgery as first line therapy

Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer